Share on LinkedInShare on LinkedIn

ARTICLE · 12 OCTOBER 2017

Shanghai Tightens Industry Interactions With HCPs

Ropes & Gray LLP
Ropes & Gray LLP
Contributor
Ropes & Gray LLP

Ropes & Gray LLP

Ropes & Gray is one of the world’s most respected law firms, with offices in key business and...

View firm profile
Explore more from Ropes & Gray LLP

In August 2017, multiple departments of Shanghai government, led by Shanghai's Health and Family Planning Commission, jointly issued a series of administrative rules to tighten the interactions...

ChinaCriminal Law

In August 2017, multiple departments of Shanghai government,1 led by Shanghai's Health and Family Planning Commission ("Shanghai HFPC"), jointly issued a series of administrative rules2 (collectively, "Recent Shanghai Rules") to tighten the interactions of pharmaceutical and medical device companies with health care professionals ("HCPs") working in Shanghai hospitals and to crack down on commercial bribery in the course of sale and procurement of medical products.

The Recent Shanghai Rules echoed and reinforced the existing mechanisms in two earlier rules issued by China's central government in late 2013 to combat corruption in the health care sector, i.e., the Regulations on the Establishment of Commercial Bribery Records for the Purchase and Sale of Medicines (also known as the "2013 Blacklisting Rules"), and the Nine Prohibitions for Strengthening Ethical Conduct in the Healthcare Industry (also known as the "2013 Nine Prohibitions"). However, the Recent

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from